Miniatura

Fitxers

e009028.full.pdf (2.96 MB)

Tipus de document

Article

Data de publicació

2024-06-01

Llicència de publicació

cc by-nc (c) Sacco, Joseph J. et al., 2024
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/214827

Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1136/jitc-2024-009028

Resum

Background: Tebentafusp, a bispecific (gp100xCD3) ImmTAC, significantly improved overall survival (OS) outcomes for HLA-A*02:01+ adult patients with untreated metastatic uveal melanoma (mUM) and showed promising survival in previously treated mUM with 1-year OS of 62% in the primary analysis of study IMCgp100-102. Here we report long-term outcomes from this phase 1/2 study in pretreated mUM. Patients and methods: Patients with previously treated mUM received tebentafusp weekly intravenous at 20 mu g dose 1, 30 mu g dose 2 and either 54, 64, 68, or 73 mu g (phase 1) or 68 mu g (phase 2) dose 3+. The primary objective was overall response rate. Secondary objectives included OS and safety. OS was estimated by Kaplan-Meier methods. Association between OS and baseline covariates, on-treatment Response Evaluation Criteria in Solid Tumors (RECIST) response, baseline tumor biopsy and circulating-tumor DNA (ctDNA) changes were assessed.Results 146 patients were treated with tebentafusp: 19 in phase 1 and 127 in phase 2. With a median follow-up duration of 48.5 months, the median OS was 17.4 months (95% CI, 13.1 to 22.8), and the 1-year, 2-year, 3-year and 4-year OS rates were 62%, 40%, 23% and 14%, respectively. Improved survival was associated with lower ctDNA baseline levels and greater ctDNA reductions by week 9 on-treatment, with 100% 1-year, 73% 2-year and 45% 3-year OS rates for patients with ctDNA clearance. Baseline gp100 expression was not associated with survival, despite more RECIST responses among patients with higher expression. No new safety signals were reported with long-term dosing.Conclusions This study represents the longest follow-up of a Tcell receptor bispecific to date and confirms the durable survival benefits achieved with tebentafusp in previously treated mUM with good tolerability long-term. A role for ctDNA reduction as an early indicator of clinical benefit was again suggested for patients treated with tebentafusp.

Matèries

Immunoteràpia, Melanoma

Matèries (anglès)

Immunotheraphy, Melanoma

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

SACCO, Joseph j., CARVAJAL, Richard d., BUTLER, Marcus o., SHOUSHTARI, Alexander n., HASSEL, Jessica c., IKEGUCHI, Alexandra, HERNANDEZ AYA, Leonel, NATHAN, Paul, HAMID, Omid, PIULATS, Josep m., RIOTH, Matthew, JOHNSON, Douglas b., LUKE, Jason j., ESPINOSA, Enrique, LEYVRAZ, Serge, COLLINS, Laura, HOLLAND, Chris, SATO, Takami. Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma. _Journal for ImmunoTherapy of Cancer_. 2024. Vol. 12, núm. 6, pàgs. e009028. [consulta: 5 de febrer de 2026]. ISSN: 2051-1426. [Disponible a: https://hdl.handle.net/2445/214827]

Exportar metadades

JSON - METS

Compartir registre